CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Rituximab for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Details

Project Number PC0180-000
Brand Name TBD
Generic Name Rituximab
Tumour Type Lymphoma & Leukemia
Indication Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar
Funding Request Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
Review Status Cancelled
Clarification The submitter notified pCODR that they will not be filing the submission.
Pre Noc Submission Yes
NOC Date
Manufacturer Sandoz Canada
Sponsor Sandoz Canada
Submission Date (Target Date)
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.